An 8-Week, Randomized, Double-Blind, Fixed Dosage, Placebo-Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-Week, Open-Label Extension (CAGO178A2302E).

Trial Profile

An 8-Week, Randomized, Double-Blind, Fixed Dosage, Placebo-Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-Week, Open-Label Extension (CAGO178A2302E).

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2012

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 18 May 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 18 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Mar 2010 Results published in the Journal of Clinical Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top